# US 2018/0021434 A1 · Topical pharmaceutical composition based on semifluorinated alkanes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021434 A1
- Document ID: US20180021434A1
- Status: Published application
- Kind: A1
- Application number: 15/721,259
- Filed: 2017-09-29
- Published: 2018-01-25
- Earliest claimed: 2011-05-25
- Assignees: Novaliq GmbH
- Inventors: Bernhard Gunther; Bastian Theisinger; Sonja Theisinger; Dieter Scherer
- Web page: https://patentgrep.com/patent/US20180021434A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 17/10: Anti-acne agents
- A61P 17/12: Keratolytics, e.g. wart or anti-corn preparations
- A61P 17/14: for baldness or alopecia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A method for delivering an active ingredient to layers of the skin below the stratum corneum comprising the step of topically administering to the skin a topical pharmaceutical composition comprising an effective amount of an active ingredient and a semifluorinated alkane according to formula
RFRH
wherein RF is a linear perfluorinated hydrocarbon segment with 4 to 12 carbon atoms, and RH is a linear alkyl group with 4 to 8 carbon atoms.

### Claim 17 (depends on 16)

The method of claim 16, wherein the active ingredient is delivered to the vital epidermis, the dermis and/or the hypodermis.

### Claim 18 (depends on 16)

The method of claim 16, wherein the semifluorinated alkane is selected from F4H5, F4H6, F4H8, F6H6 and F6H8, wherein F means a perfluorinated hydrocarbon segment, H means a non-fluorinated segment, and the number is the number of carbon atoms of the respective segment.

### Claim 19 (depends on 16)

The method of claim 16, wherein the composition is in the form of a liquid or semisolid solution, emulsion, or microemulsion.

### Claim 20 (depends on 16)

The method of claim 16, wherein the composition comprises a physiologically acceptable co-solvent selected from ethanol, acetone, ethyl acetate, isopropyl alcohol, glycerol, propylene glycol, pentylene glycol, polyethylene glycol, liquid paraffin, triglyceride oils, hydrofluorocarbons such as HFA 134a and/or HFA 227, and liquid mono- or diglycerides.

### Claim 21 (depends on 16)

The method of claim 16, wherein the skin is affected by a disease or condition selected from psoriasis, dermatitis, erythema, eczema, allergy, acne, actinic keratosis, fungal infections, bacterial infections, viral infections, verrucae, or rosacea.

### Claim 22 (depends on 16)

The method of claim 16, wherein the skin is affected by psoriasis, and wherein the active ingredient is selected from immunosuppressants or retinoids.

### Claim 23 (depends on 22)

The method of claim 22, wherein the immunosuppressant is selected from tacrolimus, sirolimus, everolimus, tacrolimus, pimecrolimus, ridaforolimus, temsirolimus, zotarolimus, and ciclosporin A.

### Claim 24 (depends on 22)

The method of claim 22, wherein the retinoid is selected from retinol, retinal, tretinoin, isotretinoin, alitretinoin, etretinate, acitretin, tazarotene, bexarotene and adapalene.

### Claim 25 (depends on 16)

The method of any of claim 16, wherein the skin is affected by acne, and wherein the active ingredient is selected from retinoids or anti-infective agents.

### Claim 26 (depends on 25)

The method of claim 25, wherein the retinoid is selected from retinol, retinal, tretinoin, isotretinoin, alitretinoin, etretinate, acitretin, tazarotene, bexarotene and adapalene.

### Claim 27 (depends on 25)

The method of claim 25, wherein the anti-infective agents is selected from azithromycin, erythromycin, clindamycin, or minocycline.

### Claim 28 (depends on 16)

The method of claim 16, wherein the skin is affected by actinic keratosis, and wherein the active ingredient is selected from diclofenac, 5-fluorouracil and imiquimod.

### Claim 29 (depends on 16)

The method of claim 16, wherein the skin is affected by a cutaneous disease involving symptoms related to inflammatory responses and the active ingredient is a corticosteroid.

### Claim 30 (depends on 16)

The method of claim 16, wherein the skin is affected by pain or itching and the active ingredient is a local anesthetic agent.

### Claim 31 (depends on 16)

The method of claim 16, wherein the skin is affected by is a fungal infection and the active ingredient is an anti-fungal agent.

### Claim 32 (depends on 16)

The method of claim 16, wherein the skin is affected by a viral infection, and the active ingredient is an anti-viral agent.

### Claim 33 (depends on 16)

The method of claim 16, wherein
i. at least about 5% of the topically administered amount of active ingredient is delivered to the vital epidermis within about 30 minutes, or
ii. at least about 5% of the topically administered amount of active ingredient is delivered to the dermis within about 30 minutes; or
iii. at least about 10% of the topically administered amount of active ingredient is delivered to the dermis within about 30 minutes; or
iv. at least about 5% of the topically administered active ingredient is delivered to the hypodermis within about 30 minutes; or
v. at least about 10% of the topically administered active ingredient is delivered to the hypodermis within about 30 minutes.

### Claim 34 (depends on 16)

The method of claim 16, wherein at least about 15% of the topically administered active ingredient is delivered to a depth of at least 10 μm within about 30 minutes.

### Claim 35 (depends on 16)

The method of claim 16, wherein at least about 20% of the topically administered active ingredient is delivered to a depth of at least 10 μm within about 30 minutes.

### Claim 36 (depends on 16)

The method of claim 16, wherein at least about 10% or at least 15% or at least about 20% of the topically administered active ingredient is delivered to a depth of at least 100 μm within about 30 minutes.
